CAS: 2416131-46-7; 3-((4-(1-(((3S)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-Dioxoisoindolin-5-yl)Pyrrolidin-3-yl)Methyl)Piperidin-4-yl)Phenyl)Amino)-5-(Piperidin-1-yl)Pyrazine-2-Carboxamide
- 英文名称3-((4-(1-(((3S)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-Dioxoisoindolin-5-yl)Pyrrolidin-3-yl)Methyl)Piperidin-4-yl)Phenyl)Amino)-5-(Piperidin-1-yl)Pyrazine-2-Carboxamide
- 中文名称3-((4-(1-(((3S)-1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-5-(哌啶-1-基)吡嗪-2-甲酰胺
- IUPAC名称3-((4-(1-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)phenyl)amino)-5-(piperidin-1-yl)pyrazine-2-carboxamide
- 其它别名2-Pyrazinecarboxamide, 3-[[4-[1-[[(3S)-1-[2-(2,6-Dioxo-3-Piperidinyl)-2,3-Dihydro-1,3-Dioxo-1H-Isoindol-5-Yl]-3-Pyrrolidinyl]Methyl]-4-Piperidinyl]Phenyl]Amino]-5-(1-Piperidinyl)-; 3-((4-(1-(((3R)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-Dioxoisoindolin-5-yl)Pyrrolidin-3-yl)Methyl)Piperidin-4-yl)Phenyl)Amino)-5-(Piperidin-1-yl)Pyrazine-2-Carboxamide; 3-[[4-[1-[[(3S)-1-[2-(2,6-Dioxo-3-Piperidyl)-1,3-Dioxo-5-Isoindolinyl]-3-Pyrrolidinyl]Methyl]-4-Piperidyl]Phenyl]Amino]-5-(1-Piperidyl)Pyrazine-2-Carboxamide; 3-((4-(1-(((3S)-1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-Dioxoisoindolin-5-yl)Pyrrolidin-3-yl)Methyl)Piperidin-4-yl)Phenyl)Amino)-5-(Piperidin-1-yl)Pyrazine-2-Carboxamide
- CAS编号2416131-46-7
- MFCD编号:MFCD34789579
- FDA UNII编号:LSC67HA8DE
- 分子式:C39H45N9O5分子量:719.85
- 产品CID: 1187688
- 产品分类Protein Tyrosine Kinase/RTK → BTK
物理性质
- 沸点949.0±65.0 °C(预测)
- 密度1.371±0.06 g/cm3(预测)
- pKa:10.83±0.40(预测)
- LogP:3.7
- 外观形态淡黄色至黄色固体
- 储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
- 产品应用该化合物是一种口服活性BTK抑制剂,它诱发变异BTC481SIN细胞降解;它比IBRUTINIB更能抑制BTTK481TMD8细胞的扩散;NX-2127促进IKAROS(IKZF1)和AIOLOS(IIKDF3)的降解,DC50值分别为25纳米和54纳米;它刺激T-细胞激活,并增强主要人类细胞的IL-2生产.
MSDS等安全信息
合成工艺路线路线简述
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1. https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-presents-positive-clinical-results-its-novel 2. https://ashpublications.org/blood/article/140/Supplement%201/2329/491381/NX-2127-001-a-First-in-Human-Trial-of-NX-2127-a 3. https://ir.nurixtx.com/static-files/034274a1-db9c-4d76-8c9a-6e22c048656d合成参考文献
参考文献:10.1016/j.ejmech.2023.115793
摘要:Zeng S, Ye Y, Xia H, Min J, Xu J, Wang Z, Pan Y, Zhou X, Huang W. Current advances and development strategies of orally bioavailable PROTACs. European Journal of Medicinal Chemistry. 2023 Dec;261():115793. doi: 10.1016/j.ejmech.2023.115793.
参考文献:10.1021/acs.jmedchem.3c01007
摘要:Robbins DW, Noviski MA, Tan YS, Konst ZA, Kelly A, Auger P, Brathaban N, Cass R, Chan ML, Cherala G, Clifton MC, Gajewski S, Ingallinera TG, Karr D, Kato D, Ma J, McKinnell J, McIntosh J, Mihalic J, Murphy B, Panga JR, Peng G, Powers J, Perez L, Rountree R, Tenn-McClellan A, Sands AT, Weiss DR, Wu J, Ye J, Guiducci C, Hansen G, Cohen F. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies. J Med Chem. 2024 Feb 22;67(4):2321–36. doi: 10.1021/acs.jmedchem.3c01007.
参考文献:10.1021/acs.jmedchem.3c01414
摘要:Huang J, Ma Z, Peng X, Yang Z, Wu Y, Zhong G, Ouyang T, Chen Z, Liu Y, Wang Q, Chen J, Chen T, Zeng Z. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. J Med Chem. 2024 Feb 22;67(4):2438–65. doi: 10.1021/acs.jmedchem.3c01414.
参考文献:10.1021/acsmedchemlett.4c00271
摘要:Lin H, Riching K, Lai MP, Lu D, Cheng R, Qi X, Wang J. Lysineless HiBiT and NanoLuc Tagging Systems as Alternative Tools for Monitoring Targeted Protein Degradation. ACS Med. Chem. Lett. 2024 Jul 28;15(8):1367–75. doi: 10.1021/acsmedchemlett.4c00271.
📝 需求与反馈
尽可能描述清楚需求与问题信息
